A clinical study is presented of 622 uric acid stone patients, constituting 34.6% of all patients with urolithiasis observed in a period of 12 years. The uric acid lithiasis in this series was essentially an upper urinary tract disease. Further evidence was obtained for idiopathic uric acid lithiasis being a disease entity, distinct from gouty uric acid lithiasis. Eighty percent of the uric acid stone patients were initially diagnosed as idiopathic uric acid lithiasis. Only 11 out of 359 patients with idiopathic uric acid lithiasis who came to follow up, developed gout. The majority of patients with idiopathic uric acid lithiasis were normouricemic and normouricosuric, only 13.6% of them became hyperuricemic during follow up. The male: female ratio in idiopathic uric acid lithiasis was 2.7:1, as compared with 12.3:1 in gouty uric acid lithiasis. In both the idiopathic and gouty uric acid lithiasis groups there was a preponderance of patients of European origin as compared with those of Near Eastern-Mediterranean origin. Myeloproliferative disease constituted a rare etiology in this series. There was a striking association of uric acid lithiasis with hyperparathyroidism, the latter occurring in 10.4% of the uric acid stone patients. Surgery and urinary tract infection was frequent.

This content is only available via PDF.
© 1970 S. Karger AG, Basel
1970
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.